Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia

ClinicalTrials.gov ID: NCT02605122

Public ClinicalTrials.gov record NCT02605122. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2/3, Randomized, Open-Label, Multi-center Study to Determine the Safety and Efficacy of Solithromycin in Adolescents and Children With Suspected or Confirmed Community-Acquired Bacterial Pneumonia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase 2/3, randomized, open-label, active control, multi-center study to assess the safety and efficacy of solithromycin in children and adolescents with community-acquired bacterial pneumonia (CABP).

Study identification

NCT ID: NCT02605122
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Enrollment: 97 participants

Conditions and interventions

Conditions

Community-acquired Bacterial Pneumonia

Interventions

Solithromycin Drug
Standard of Care Drug

Drug

Eligibility (public fields only)

Age range: 2 Months to 17 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 2016 (Actual)
Primary completion: Mar 21, 2018 (Actual)
Completion: Mar 21, 2018 (Actual)
Last update posted: Jan 3, 2019

2016 – 2018

United States locations

U.S. sites: 21
U.S. states: 14
U.S. cities: 21

Facility	City	State	ZIP	Site status
Not listed	Little Rock	Arkansas	72202	—
Not listed	Los Angeles	California	90095	—
Not listed	Sacramento	California	95817	—
Not listed	San Diego	California	92123	—
Not listed	Washington D.C.	District of Columbia	20010	—
Not listed	Tampa	Florida	33606	—
Not listed	Louisville	Kentucky	40202	—
Not listed	Omaha	Nebraska	68198-2162	—
Not listed	Las Vegas	Nevada	89102	—
Not listed	Durham	North Carolina	27710	—
Not listed	Greenville	North Carolina	27834	—
Not listed	Toledo	Ohio	43606	—
Not listed	Portland	Oregon	97239	—
Not listed	Hershey	Pennsylvania	17033	—
Not listed	Memphis	Tennessee	38105	—
Not listed	Amarillo	Texas	79106	—
Not listed	Houston	Texas	77030	—
Not listed	Splendora	Texas	77372	—
Not listed	Charlottesville	Virginia	22905	—
Not listed	Richmond	Virginia	29298	—
Not listed	Roanoke	Virginia	24013	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02605122, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 3, 2019 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02605122 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →